Brief: Mabion Gets Permission For Briding Clinical Trial Of MabionCD20 Drug For Rheumatoid Arthritis Patients
11/10/2021 17:31
Oct 11 (Reuters) - Mabion SA MABP.WA :
* SAYS GETS PERMISSION FROM POLAND'S MEDICINES AUTHORITY TO
RUN
BRIDING CLINICAL TRIAL OF MABIONCD20 DRUG FOR RHEUMATOID
ARTHRITIS PATIENTS
Source text for Eikon: ID:nEM7c8XV1a
Further company coverage: MABP.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Mabion SA
See all newsBrief: Mabion Signs Annex To Extend Production Agreement With Novavax To End of 2029
Brief: Mabion Signs Deal With Oddifact Sas On Preparing Mabioncd20 For FDA Consultation
Brief: Mabion Q1 Net Loss 9.7 Million Zlotys
Brief: Mabion Signs LoI With Oddifact On Use Of MabionCD20 Drug For Orphan Diseases
Brief: Mabion FY Net Loss 62.6 Million Zlotys